FORM OF COMMON STOCK WARRANT AGREEMENTCommon Stock Warrant Agreement • March 15th, 2022 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 15th, 2022 Company Industry JurisdictionThis Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
aTyr Pharma, Inc. and _____________, As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of __________Preferred Stock Warrant Agreement • March 15th, 2022 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 15th, 2022 Company Industry JurisdictionThis Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
aTyr Pharma, Inc. and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of __________Securities Warrant Agreement • March 15th, 2022 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 15th, 2022 Company Industry JurisdictionThis Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
aTyr Pharma, INC., Issuer AND [TRUSTEE], TrusteeaTYR PHARMA INC • March 15th, 2022 • Biological products, (no disgnostic substances) • New York
Company FiledMarch 15th, 2022 Industry JurisdictionWhereas, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;